EXPANDING BONE MARROW-DERIVED IMMUNE REGULATORY CELLS AND IMMUNE REGULATORY B CELLS BY ACTIVATING GPCR19 PATHWAY IN VIVO OR IN VITRO

• Main Authors: CHANG, SOOG HEE, KIM, YOUN HEE, SEONG, SEUNG YONG, KIM, YOUNG JOO, JUNG, HI EUN
• Format: Patent
• Language: English; Korean
• Published: 23.09.2013
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPIRITS; VINEGAR; WINE

PURPOSE: Proliferation of bone marrow-derived immune regulatory cells and immune regulatory B lymphocytes in vivo and in vitro is provided to show a method for screening a therapeutic agent for treating GPCR19-related diseases or a method for analyzing efficacy of a GPCR19 agonist, thereby producing an anti-inflammatory pharmaceutical composition. CONSTITUTION: An immune regulatory B cell is transformed or proliferated by treatment with a toll-like receptor (TLR) signal transduction inducing factor and a GPCR19 agonist. The B cells show Gr-1^+CD11b^+ phenotype on the surface by treatment with the TLR signal transduction inducing factor and the GPCR19 agonist. The B cells show CD23^hi phenotype on the surface and have an anti-inflammatory activity by treatment with myeloid-derived suppressor cells (MDSC) having an anti-inflammatory activity. The B cells express CD21 and CD23. The TLR signal transduction inducing factor is lipopolysaccharide (LPS) or peptidoglycan. The GPCR19 agonist is a compound of chemical formula 1 or a salt or a hydrate thereof.